Back to Archived News
Helix BioMedix Secures Additional Intellectual Property
Thursday, November 19, 2009
Striking™ Skin Care Technology Covered in Allowed Claims
Bothell, WA -- Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, today announced the United States Patent and Trademark Office has allowed multiple claims in one of the company’s recent patent applications. US patent application 12/005653, "Short Bioactive Peptides for Cellular and Immunological Modulation," covers a number of peptides including Heptapeptide-7, a SmartPeptides™ technology and lead component in the Striking™ Skin Care line. The patent is expected to issue shortly.
Striking Skin Care and Heptapeptide-7 are specifically designed for peri- and post-menopausal skin. Clinical data demonstrating the significant benefits of Striking Skin Care has been accepted for publication in a leading dermatology journal in early 2010 and will be presented at a number of 2010 dermatology and aesthetic conferences including the 8th Annual Meeting of the Society of Dermatology Skin Care Specialists in Miami in March. In addition, Heptapeptide-7 will also be featured in a technology innovation article in the December issue of the trade journal HAPPI.
Helix BioMedix Chief Scientific Officer Dr. Tim Falla commented, "We pride ourselves on the company’s strong and growing IP portfolio and greatly appreciate the dermatology community’s enthusiastic response to its commercialization through Striking Skin Care with SmartPeptides. Our extensive library now comprises more than 80 issued and pending US and foreign patents covering the largest peptide portfolio of its kind."
About Helix BioMedix, Inc.
Helix BioMedix, Inc. is a biopharmaceutical company with an extensive library of diverse bioactive peptides and patents covering six distinct classes and hundreds of thousands of peptide sequences. Core competencies include peptide design, synthesis and characterization together with assay development, screening, tissue culture and microbiology, leveraged through relationships with contract research organizations and peptide manufacturers. The company takes product development programs from theoretical concept to a validated and qualified skin care active ingredient fully validated as to efficacy and safety. Applications for Helix BioMedix peptides include anti-aging cosmeceutical skin care and acne treatment as well as other topical anti-infective pharmaceuticals and wound healing applications. Striking, SmartPeptides and HB-Aminobright are trademarks of Helix BioMedix, Inc. More information about the company and its proprietary peptides may be found on the company’s website at www.helixbiomedix.com.
Forward Looking Statements
This press release contains forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding activities, events or developments that the company expects, believes or anticipates may occur in the future, including statements related to its potential growth, product development and commercialization and revenue. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the company's ability to successfully raise additional capital, enter into revenue generating license agreements, continue its research and development efforts, including pre-clinical and clinical studies, and continue developing marketable peptide-based products, and general economic conditions. Additional assumptions, risks and uncertainties are described in detail in the company’s reports and other filings with the Securities and Exchange Commission. Such filings are available on the company’s website or at www.sec.gov. Readers are cautioned that such forward-looking statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances.
Back to Archived News